FABP1 and metabolic dysfunction-associated steatohepatitis: These results indicate that pemafibrate treatment significantly reduces the severity of MASH-induced intestinal LCFA absorption abnormalities; however, the Mtp and Fabp1 levels in the MASH may still be higher than those in the healthy control levels, and complete normalization may not be achieved.